Articles tagged with Tumor Regression
The Alliance QUANTUM trial is testing whether post-transplant consolidation therapy with teclistamab improves survival in patients with primary plasma cell leukemia. Plasma cell leukemia is a rare but aggressive blood cancer with poor long-term survival rates.
A multicenter clinical trial found that implanting collagen tiles during brain surgery improved tumor control and lowered the risk of recurrence by 12.1% compared to current standard of care. Patients treated with tile-based radiation therapy (TBRT) had a median overall survival of 42.5 months, more than double the 17.6 months seen wit...
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
A new clinical study aims to improve communication between patients and families about genetic risks of colorectal cancer. The trial will compare two methods of sharing genetic test results with close relatives, with the goal of learning which approach helps more family members get necessary genetic testing.
A study published in PNAS successfully eliminated pancreatic tumours in mice completely and durably, with no significant side effects. The treatment, combining three molecular targets, induced robust regression of experimental PDACs without causing tumor resistance.
A new clinical trial, RECIPROCAL, seeks to optimize targeted radiation therapy for men with advanced prostate cancer by adjusting treatment based on individual PSA levels. The trial aims to minimize side effects while preserving survival benefits.
A recent review suggests that Clostridioides difficile infection may promote the development of gastrointestinal tumors, including colorectal cancer. The bacterium's toxins can cause damage to the epithelial cytoskeleton and induce inflammation, leading to chronic colitis and increased risk of CRC.
A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.
A phase two trial found that adding dinutuximab beta to chemotherapy improves the best objective response rate and overall survival time for children with relapsed or refractory neuroblastoma. The treatment resulted in a significant increase in patients' tumors shrinking after six cycles of treatment.
A microRNA cocktail has been developed to weaken glioblastoma, a type of aggressive brain tumor. The formulation, comprising 11 different non-coding RNAs, slows the growth of cancer cells and enhances chemotherapeutic drug activity.
A study published in Molecular Cancer suggests that blocking the thyroid hormone receptor Beta, TRβ, can inhibit the growth of prostate cancer cells. This discovery may lead to a new way of treating certain types of aggressive prostate cancer.
A new Alliance trial is exploring the effectiveness of a combination of targeted therapy and immunotherapy for patients with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study aims to improve disease control and quality of life for patients with limited treatment options.
BH3 mimetics demonstrate potent anti-cancer activity by targeting pro-survival BCL-2 proteins, effectively eradicating leukaemia cells with complex mutations. The review highlights several important findings about BH3 mimetics and their role in treating acute myeloid leukaemia.
Researchers have developed a novel therapeutic approach that combines difluoromethylornithine with a targeted diet to enhance the effectiveness of treatment in high-risk neuroblastoma patients. The diet blocks the formation of polyamine precursors, amplifying the drug's effects and driving cancer cells to mature.
Researchers developed pH-responsive graphene-based nanocarriers that can target cancer cells, achieving efficient and safe drug delivery. The material's surface charge adapted to the acidic tumor environment, allowing it to bind and enter cancer cells while avoiding healthy tissues.
A new treatment approach using cyclophosphamide has been found to prevent most graft-versus-host disease in mismatched transplants. The study shows that 80% of patients are alive after a year, similar to outcomes seen in fully matched transplants.
Researchers have identified a hidden molecular mechanism involving two proteins that allows tumors to resist treatment. A new gelatin-based nanoparticle has been developed to shut down both proteins simultaneously, showing promising results in early studies with mice.
Researchers examined baseline characteristics of adolescent and young adult (AYA) cancer survivors seen in oncology primary care clinic, finding high rates of comorbidities and cardiovascular disease. They also studied the overexpression of IRAK4 protein in acute myeloid leukemia (AML) cells, with potential implications for treatment.
Researchers identify five distinct immunotypes in tongue squamous cell carcinoma, shedding light on why current immunotherapies fail. The study's findings highlight the need for immune-based assessments to guide treatment decisions and suggest a new approach to personalized medicine.
Pennington Biomedical welcomes Dr. Adithya Hari, MD, with expertise in nuclear oncology and translational science, strengthening cancer research and patient-centered innovation in Louisiana. He will establish a research program focused on nuclear medicine and dedicate time to direct patient care through a clinical partnership.
A predictive model combining tumor marker readings with patients' genetic profiles enhances predictions for patient survival and surgery decision-making. The new tool accurately identifies candidates who would benefit from surgery, suggesting that current tumor marker evaluations are inadequate for these genetic profiles.
A new study has identified macrophage activity as a key predictor of which skin cancer patients are most likely to respond to immunotherapy. The findings aim to improve personalized medicine for cancer patients and enable clinicians to select effective treatments, reducing side effects and costs.
Researchers discovered a novel vulnerability in prostate cancer cells that starves them of critical nutrients called amino acids. By inhibiting two proteins, GCN2 and p53, the team found a way to effectively destroy prostate tumors.
Researchers explore immune activation and tumor-promoting transcription factor FOXM1's role in CDK4/6-MEK resistance. They suggest targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 as future treatment options for MPNST patients.
Researchers describe a new concept for an immune response against cancer and aging using senescent cell-derived vaccines. The vaccines aim to stimulate the immune system against cancer cells and slow down or reverse aging-related diseases.
Researchers at Mass General Cancer Center have achieved dramatic tumor regression in glioblastoma patients after receiving next generation CAR-T therapy. The treatment, known as INCIPIENT, combines two forms of therapy to target mixed cell populations within tumors.
Researchers from Japan have discovered a novel targeted molecular therapy using microRNA-451a to suppress the progression of gemcitabine-resistant biliary tract cancers. The study found that miR-451a significantly diminished cell proliferation, induced cell death, and reduced chemoresistance in cancer cells.
Researchers found that apoptotic cells induce apoptosis in neighboring hair follicle cells during the regression cycle. The study proposes a mathematical model of the hair follicle regression cycle, which suggests that the dermal papilla plays an essential role in initiating apoptosis.
Analysis of rare cancer patients treated with checkpoint inhibitors reveals a linear correlation between tumor shrinkage and patient survival, contradicting earlier threshold-based models. The study suggests that using partial- or complete-response rates may miss signals of longer survival.
A new study found that the antibody-drug conjugate STRO-001 showed nanomolar cytotoxicity in 88% of cancer cell lines tested, with potent efficacy against proliferating B cells. The research supports ongoing clinical studies for patients with B-cell non-Hodgkin lymphoma.
A new method utilizes an unnatural sugar to anchor cytokines to T cells, enhancing their functions without systemic side-effects. The approach has shown promise in stimulating the host immune system against tumor cells and inhibiting tumor growth in mice with melanoma.
Researchers at MD Anderson Cancer Center have discovered a novel triple immunotherapy combination targeting checkpoints in T cells and myeloid suppressor cells, improving anti-tumor responses and survival rates in preclinical models of pancreatic cancer. The study found that neutralizing specific immunosuppressive mechanisms dramatical...
A nationwide retrospective study showed that adjuvant chemotherapy after neo-adjuvant chemotherapy and surgery significantly improved overall survival in patients with pancreatic adenocarcinoma, regardless of lymph node status or resection margins. The study included nearly 900 patients and was published in JAMA Oncology.
Researchers have discovered two novel drugs that can block the growth and shrink the size of schwannoma tumors, a type of nerve sheath tumor found in the nervous system. The treatment works by inhibiting the Hippo signaling pathway, which is dysregulated in multiple types of cancer.
Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...
Researchers identified CUDC907 as a dual phosphoinositide-3 kinase/histone deacetylase inhibitor that promotes apoptosis in NF2 schwannoma cells. The compound reduced viability and induced cell cycle arrest in human merlin deficient Schwann cell models.
Researchers at Baylor College of Medicine have identified a combination therapy that targets both tumor cells and macrophages to treat triple-negative breast cancer. The therapy resulted in durable tumor regression and immune memory in animal models, suggesting potential for improved treatment outcomes.
Scientists at Japan Advanced Institute of Science and Technology have created nanoengineered bacteria for photothermal cancer immunotheranostics. The synthesized nanoparticles showed powerful photothermal conversion, high biocompatibility, and excellent tumor selectivity, facilitating clear fluorescent tumor visualization.
A comparative trial found that exercise 'prehab' significantly enhanced tumour shrinkage and downstaging in patients with operable oesophageal cancer. The study showed improved skeletal muscle mass, reduced visceral fat, and a stronger immune response in the prehab group compared to conventional care.
Researchers used a patient's own immune cells to target unique mutations in tumor DNA, leading to measurable tumor shrinkage in 67% of patients with metastatic breast cancer. The approach has potential as a personalized treatment for hormone receptor-positive breast cancers.
Researchers at Houston Methodist have discovered a new combination therapy that regresses tumor growth of triple negative breast cancer and prevents the cancer from spreading. The response rate using this therapy is about 50%, compared to 25-30% with older drugs, offering new hope for patients with hard-to-treat breast cancers.
A recent study found that pathologic complete response rates did not differ by racial groups, but HR-positive/HER2-negative breast cancer showed a significant survival disparity between Black and white women. The study suggests that tumor molecular subtype is a more significant factor in breast cancer survival than race.
A recent review article describes a class of viruses known as oncolytic viruses, which have the remarkable ability to target and destroy cancer cells. Researchers are exploring these viruses for cancer therapy, with some showing promising results in stimulating an immune response against cancer.
A woman with non-small cell lung cancer experienced a 76% tumor reduction after taking CBD oil for 2.5 years, raising hopes for alternative cancer treatments. However, more research is needed to confirm the mechanism of action and potential side effects.
Researchers at Université catholique de Louvain have discovered a molecule that blocks immune responses in cancer patients, and are now developing an immunotherapy to neutralize it. The treatment combines anti-GARP antibodies with another proven approach to increase effectiveness in fighting cancer.
A recent study published in Genetics found a single genetic mutation in Tasmanian devils that leads to reduced growth of a transmissible cancer. The mutation is also implicated in human prostate and colon cancers, suggesting potential new treatment avenues.
A new pathological grading system evaluates the therapeutic effect of neoadjuvant chemotherapy for metastatic lymph nodes in esophageal cancer patients. The system predicts recurrence and prognosis more accurately than conventional methods.
Researchers have found large clones of skin cells caused by UV exposure can be targeted to reduce skin cancers. This study suggests that stopping these clones may help win the battle against skin cancer.
Researchers have designed a novel probiotic strain that can seek out solid tumors and safely deliver immune checkpoint inhibitors, leading to tumor regression. The probiotic platform can also be used to deliver multiple immunotherapies simultaneously, enabling effective therapeutic combinations for difficult-to-treat cancers.
A new study from American Cancer Society investigators reveals that cancer survivors enrolled in high deductible health plans (HDHPs) are more likely to report delaying or foregoing medical care due to cost concerns. Meanwhile, individuals with HDHPs who also have health savings accounts (HSAs) may experience less delayed care.
Scientists at Washington State University have discovered genes involved in Tasmanian devil facial tumor disease regression. Genetic variations found in devils that didn't die from tumors may also help humans and other mammals with similar conditions.
A study published in Nature identified a tumor cell population responsible for resistance to therapy and tumor relapse in basal cell carcinoma. The researchers found that vismodegib promotes the differentiation of tumor cells, leading to their elimination, but also reveals a dormant population of tumor cells with active Wnt signaling.
A recent study found that canine transmissible venereal tumors regress quickly due to the immune system's response, involving chemokines and host skin cells. The findings may lead to more effective therapeutic strategies for various human cancers.
Regular monitoring for cervical intra-epithelial neoplasia grade 2 (CIN2) is justified, as many moderate lesions regress spontaneously, especially in women under 30. After two years of active surveillance, half of the lesions have regressed, while one third persist and just over a fifth progress to CIN3 or worse.
Researchers at Hokkaido University have developed a chimeric anti-PD-L1 antibody that induces immune responses and tumor regression in dogs with malignant cancers. The antibody targets PD-L1-positive cancers, including oral malignant melanoma and undifferentiated sarcoma.
Researchers found that neoadjuvant immunotherapy with nivolumab was safe and did not delay surgery in patients with early-stage non-small-cell lung cancer. Six of 15 patients experienced major pathological regression, suggesting potential activity of anti-PD-1 immunotherapy in early stage lung cancer.
A phase I study of LOXO-101 demonstrated efficacy in reducing tumors in six patients with TRK fusion-positive cancers, including sarcoma, thyroid, and non-small cell lung. The study showed significant tumor regression in all six patients, with one patient experiencing a 17% tumor reduction.
A study examines the safety of propranolol therapy in infants with vascular tumors, finding severe respiratory and cardiac disorders are rare but significant. The treatment has been shown to induce regression, but caution is advised due to potential risks.